Jiang et al. unveiled the therapeutic potential of miRNA-500a-3p in cisplatin-induced AKI, which could inhibit NF-κB-driven necrotic inflammation of renal epithelial cells (Jiang et al., 2019). Here, NFKB1 is linked to acute kidney injury.